S. Trabelsi

Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration: MARIMUNO-ANRS 145 Study

L. Cuzin, G. Peytavin, P. Delobel, 2012, Journal of acquired immune deficiency syndromes.

High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.

D. Costagliola, N. Mounier, F. Raffi, 2015, Clinical Infectious Diseases.

Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART

R. Tubiana, E. Lanoy, D. Costagliola, 2013, AIDS.

Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals.

B. Autran, L. Cuzin, J. Lavigne, 2013, Blood.